OSR (OSRH) shares surged 116% amid heavy trading after the company's Vaximm subsidiary said Wednesday the final data from a phase 2a trial showed its investigational vaccine VXM01 in combination with avelumab "could offer meaningful clinical benefit" in patients with recurrent glioblastoma, a type of aggressive brain cancer.
Intraday trading volume catapulted to over 75.2 million shares from a daily average of about 1.2 million.
VivoPower International (VVPR) said Wednesday it is in advanced talks with Abu Dhabi-based Energi Holdings on an unsolicited all-cash takeover bid for $120 million. Negotiations between VivoPower's board and Energi are expected to be completed by April 2.
Shares soared 75% as intraday trading volume surged to more than 132 million from a daily average of about 2.7 million.
SurgePays (SURG) said overnight that it expects revenue to exceed $200 million over the next 12 months, compared with sales of $60.9 million reported in 2024.
Shares jumped 61% as intraday trading volume soared to over 63.9 million from a daily average of roughly 295,000.
Price: 3.46, Change: +1.86, Percent Change: +116.44
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。